BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 16457333)

  • 1. [Pneumocystis jiroveci pneumonia as a complication of glucocorticoid therapy for interstitial pneumonia].
    Enomoto T; Azuma A; Matsumoto A; Nei T; Hiramatsu K; Abe S; Usuki J; Kudoh S
    Nihon Kokyuki Gakkai Zasshi; 2005 Dec; 43(12):725-30. PubMed ID: 16457333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preventive effect of sulfamethoxasole-trimethoprim on Pneumocystis jiroveci pneumonia in patients with interstitial pneumonia.
    Enomoto T; Azuma A; Matsumoto A; Nei T; Fujita K; Hattori K; Saito Y; Abe S; Usuki J; Kudoh S
    Intern Med; 2008; 47(1):15-20. PubMed ID: 18175999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacies of atovaquone, pentamidine, and trimethoprim/sulfamethoxazole for the prevention of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases.
    Kitazawa T; Seo K; Yoshino Y; Asako K; Kikuchi H; Kono H; Ota Y
    J Infect Chemother; 2019 May; 25(5):351-354. PubMed ID: 30711257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pneumocystis carinii pneumonia in patients with connective tissue disease.
    Li J; Huang XM; Fang WG; Zeng XJ
    J Clin Rheumatol; 2006 Jun; 12(3):114-7. PubMed ID: 16755237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pneumocystis jirovecii pneumonia in patients with autoimmune disease on high-dose glucocorticoid.
    Chew LC; Maceda-Galang LM; Tan YK; Chakraborty B; Thumboo J
    J Clin Rheumatol; 2015 Mar; 21(2):72-5. PubMed ID: 25710857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pneumocystis jiroveci pneumonia prophylaxis during maintenance therapy influences methotrexate/6-mercaptopurine dosing but not event-free survival for childhood acute lymphoblastic leukemia.
    Levinsen M; Shabaneh D; Bohnstedt C; Harila-Saari A; Jonsson OG; Kanerva J; Lindblom A; Lund B; Andersen EW; Schmiegelow K;
    Eur J Haematol; 2012 Jan; 88(1):78-86. PubMed ID: 21854453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful prophylaxis against Pneumocystis carinii pneumonia in HIV-infected children using smaller than recommended dosages of trimethoprim-sulfamethoxazole.
    Fisher RG; Nageswaran S; Valentine ME; McKinney RE
    AIDS Patient Care STDS; 2001 May; 15(5):263-9. PubMed ID: 11530767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A dose-escalation regimen of trimethoprim-sulfamethoxazole is tolerable for prophylaxis against Pneumocystis jiroveci pneumonia in rheumatic diseases.
    Takenaka K; Komiya Y; Ota M; Yamazaki H; Nagasaka K
    Mod Rheumatol; 2013 Jul; 23(4):752-8. PubMed ID: 22907597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-day trimethoprim/sulfamethoxazole prophylaxis for Pneumocystis pneumonia in children with cancer.
    Caselli D; Petris MG; Rondelli R; Carraro F; Colombini A; Muggeo P; Ziino O; Melchionda F; Russo G; Pierani P; Soncini E; DeSantis R; Zanazzo G; Barone A; Cesaro S; Cellini M; Mura R; Milano GM; Meazza C; Cicalese MP; Tropia S; De Masi S; Castagnola E; Aricò M;
    J Pediatr; 2014 Feb; 164(2):389-92.e1. PubMed ID: 24252793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolerability of low-dose sulfamethoxazole/trimethoprim for Pneumocystis jirovecii pneumonia prophylaxis in kidney transplant recipients.
    Zmarlicka M; Martin ST; Cardwell SM; Nailor MD
    Prog Transplant; 2015 Sep; 25(3):210-6. PubMed ID: 26308779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical characteristics of Pneumocystis carinii pneumonia in children with systemic lupus erythematosus].
    Tang XY; Li J; Dong F; Song HM
    Zhonghua Er Ke Za Zhi; 2013 Dec; 51(12):920-4. PubMed ID: 24495763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and safety of lower dose sulfamethoxazole/trimethoprim therapy for Pneumocystis jirovecii pneumonia in patients with systemic rheumatic diseases: A retrospective multicenter study.
    Ohmura SI; Naniwa T; Tamechika SY; Miyamoto T; Shichi D; Kazawa N; Iwagaitsu S; Maeda S; Wada JI; Niimi A
    J Infect Chemother; 2019 Apr; 25(4):253-261. PubMed ID: 30642768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids-clinical implication of primary prophylaxis using trimethoprim-sulfamethoxazole.
    Park JW; Curtis JR; Kim MJ; Lee H; Song YW; Lee EB
    Arthritis Res Ther; 2019 Sep; 21(1):207. PubMed ID: 31521185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?
    ; Mocroft A; Reiss P; Kirk O; Mussini C; Girardi E; Morlat P; Stephan C; De Wit S; Doerholt K; Ghosn J; Bucher HC; Lundgren JD; Chene G; Miro JM; Furrer H
    Clin Infect Dis; 2010 Sep; 51(5):611-9. PubMed ID: 20645862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pneumocystis pneumonia in a renal transplant recipient].
    Özkoç S; İnceboz T; Sıfıl A; Tuncay S; Akisü Ç
    Turkiye Parazitol Derg; 2010; 34(4):186-9. PubMed ID: 21391190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No occurrence of Pneumocystis jiroveci (carinii) pneumonia in 120 adults undergoing myeloablative unrelated cord blood transplantation.
    Tomonari A; Takahashi S; Ooi J; Tsukada N; Konuma T; Kato S; Kasahara S; Iseki T; Tojo A; Asano S
    Transpl Infect Dis; 2008 Oct; 10(5):303-7. PubMed ID: 18564982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Twice weekly Pneumocystis jiroveci pneumonia prophylaxis with trimethoprim-sulfamethoxazole in pediatric patients with acute lymphoblastic leukemia.
    Agrawal AK; Chang PP; Feusner J
    J Pediatr Hematol Oncol; 2011 Jan; 33(1):e1-4. PubMed ID: 21102354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation.
    Colby C; McAfee S; Sackstein R; Finkelstein D; Fishman J; Spitzer T
    Bone Marrow Transplant; 1999 Oct; 24(8):897-902. PubMed ID: 10516703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology and risk factors associated with Pneumocystis jirovecii pneumonia in kidney transplant recipients after 6-month trimethoprim-sulfamethoxazole prophylaxis: A case-control study.
    Park SY; Jung JH; Kwon H; Shin S; Kim YH; Chong YP; Lee SO; Choi SH; Kim YS; Woo JH; Kim SH; Han DJ
    Transpl Infect Dis; 2020 Apr; 22(2):e13245. PubMed ID: 31943590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced toxicity with gradual initiation of trimethoprim-sulfamethoxazole as primary prophylaxis for Pneumocystis carinii pneumonia: AIDS Clinical Trials Group 268.
    Para MF; Finkelstein D; Becker S; Dohn M; Walawander A; Black JR
    J Acquir Immune Defic Syndr; 2000 Aug; 24(4):337-43. PubMed ID: 11015150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.